Jason Broderick

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.

The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

A supplemental new drug application has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma.

Less than 2 years after checkpoint blockade immunotherapy first became available for patients with non-small cell lung cancer, the PD-1 inhibitor pembrolizumab is poised to reshape the treatment paradigm for previously untreated individuals without molecular mutations.

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

ASCO named the vastly improved outlook for patients with chronic lymphocytic leukemia as its inaugural "Cancer Advance of the Year."

As the Avastin (bevacizumab) drama continues at the FDA, the National Comprehensive Cancer Network (NCCN) has weighed in.

Three hot gadgets for Oncologists.

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.